Latigo Biotherapeutics Granted FDA Fast Track Designation for LTG-001, Potential Best-in-Class Nav1.8 Inhibitor for the Non-Opioid Treatment of Acute Pain

LTG-001 demonstrated favorable safety and tolerability profile with predictable pharmacokinetics in Phase 1 trial Fast Track designation will facilitate development and expedited regulatory review of LTG-001 THOUSAND OAKS, Calif., March 3, 2025 /PRNewswire/ — Latigo Biotherapeutics…